Search

Your search keyword '"Bancroft GJ"' showing total 105 results

Search Constraints

Start Over You searched for: Author "Bancroft GJ" Remove constraint Author: "Bancroft GJ"
105 results on '"Bancroft GJ"'

Search Results

3. A new in vivo model to test anti-tuberculosis drugs using fluorescence imaging.

4. A live experimental vaccine against Burkholderia pseudomallei elicits CD4+ T cell-mediated immunity, priming T cells specific for 2 type III secretion system proteins.

5. Glibenclamide alters interleukin-8 and interleukin-1β of primary human monocytes from diabetes patients against Mycobacterium tuberculosis infection.

6. Immune responses in beta-thalassaemia: heme oxygenase 1 reduces cytokine production and bactericidal activity of human leucocytes.

7. Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis.

8. Genome Resequencing of Laboratory Stocks of Burkholderia pseudomallei K96243.

9. Glibenclamide Reduces Primary Human Monocyte Functions Against Tuberculosis Infection by Enhancing M2 Polarization.

10. Inactivation of bpsl1039-1040 ATP-binding cassette transporter reduces intracellular survival in macrophages, biofilm formation and virulence in the murine model of Burkholderia pseudomallei infection.

11. Burkholderia pseudomallei and Burkholderia mallei vaccines: Are we close to clinical trials?

12. A proteasome inhibitor produced by Burkholderia pseudomallei modulates intracellular growth.

13. Boosting of post-exposure human T-cell and B-cell recall responses in vivo by Burkholderia pseudomallei-related proteins.

14. Interleukin 10 inhibits pro-inflammatory cytokine responses and killing of Burkholderia pseudomallei.

15. Glibenclamide impairs responses of neutrophils against Burkholderia pseudomallei by reduction of intracellular glutathione.

16. Differential Production of Type I IFN Determines the Reciprocal Levels of IL-10 and Proinflammatory Cytokines Produced by C57BL/6 and BALB/c Macrophages.

17. CD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis Infection.

18. Identification of an OmpW homologue in Burkholderia pseudomallei, a protective vaccine antigen against melioidosis.

19. Burkholderia pseudomallei kynB plays a role in AQ production, biofilm formation, bacterial swarming and persistence.

20. Characterization of New Virulence Factors Involved in the Intracellular Growth and Survival of Burkholderia pseudomallei.

21. The Blood Transcriptome of Experimental Melioidosis Reflects Disease Severity and Shows Considerable Similarity with the Human Disease.

22. Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system.

23. Programmed death ligand 1 on Burkholderia pseudomallei-infected human polymorphonuclear neutrophils impairs T cell functions.

24. Deletion of zmp1 improves Mycobacterium bovis BCG-mediated protection in a guinea pig model of tuberculosis.

25. CD4+ T cell epitopes of FliC conserved between strains of Burkholderia: implications for vaccines against melioidosis and cepacia complex in cystic fibrosis.

26. Glibenclamide reduces pro-inflammatory cytokine production by neutrophils of diabetes patients in response to bacterial infection.

27. Rapid in vivo assessment of drug efficacy against Mycobacterium tuberculosis using an improved firefly luciferase.

28. The condition-dependent transcriptional landscape of Burkholderia pseudomallei.

29. Production of interleukin-27 by human neutrophils regulates their function during bacterial infection.

30. Blockade of IL-10 signaling during bacillus Calmette-Guérin vaccination enhances and sustains Th1, Th17, and innate lymphoid IFN-γ and IL-17 responses and increases protection to Mycobacterium tuberculosis infection.

31. Role of RelA and SpoT in Burkholderia pseudomallei virulence and immunity.

32. Development of vaccines against burkholderia pseudomallei.

33. Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis.

34. Low-dose exposure of C57BL/6 mice to burkholderia pseudomallei mimics chronic human melioidosis.

35. Human immune responses to Burkholderia pseudomallei characterized by protein microarray analysis.

36. Burkholderia pseudomallei proteins presented by monocyte-derived dendritic cells stimulate human memory T cells in vitro.

37. CD4+ T-cell immunity to the Burkholderia pseudomallei ABC transporter LolC in melioidosis.

38. Protective cellular responses to Burkholderia mallei infection.

39. Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung.

40. Optimisation of bioluminescent reporters for use with mycobacteria.

41. Sensitive detection of gene expression in mycobacteria under replicating and non-replicating conditions using optimized far-red reporters.

42. Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis.

43. Phenotypic and functional characterization of human memory T cell responses to Burkholderia pseudomallei.

44. Burkholderia pseudomallei: animal models of infection.

45. The case for hypervirulence through gene deletion in Mycobacterium tuberculosis.

46. Altered proteome in Burkholderia pseudomallei rpoE operon knockout mutant: insights into mechanisms of rpoE operon in stress tolerance, survival, and virulence.

47. Development of signature-tagged mutagenesis in Burkholderia pseudomallei to identify genes important in survival and pathogenesis.

48. A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei.

49. Critical role of type 1 cytokines in controlling initial infection with Burkholderia mallei.

50. Role of T cells in innate and adaptive immunity against murine Burkholderia pseudomallei infection.

Catalog

Books, media, physical & digital resources